Brief: Candel Therapeutics Changes Primary Endpoint Of Its Phase 2 Clinical Trial Of CAN-2409

Candel Therapeutics

22/02/2023 14:40

Feb 22 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS INC -  CHANGED PRIMARY ENDPOINT OF ITS
RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF
CAN-2409
    * CANDEL THERAPEUTICS INC - CHANGE WILL AFFECT TIMING OF TOP
LINE
RESULTS THAT WERE PREVIOUSLY GUIDED TO BE IN Q4 OF 2023
    * CANDEL THERAPEUTICS INC - CURRENTLY ANTICIPATES TOP-LINE
RESULTS
TO BE AVAILABLE IN Q4 OF 2024
    * CANDEL -ADDITIONAL FOLLOW-UP TIME REQUIRED TO ACCUMULATE
SUFFICIENT EVENTS TO DETECT REDUCTION IN HAZARD FOR
PROGRESSION/DEATH BEFORE TRIAL UNBLINDING

Further company coverage:  CADL.O 
 ((Reuters.Briefs@thomsonreuters.com;))